secwatch / observer
8-K filed April 25, 2024, 7:59 PM ET CIK 0001845459
other material confidence high sentiment neutral materiality 0.55

NKGen Biotech amends forward purchase agreement, sets floor price at $1.2743 and allows 248,360 additional shares

NKGen Biotech, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

NKGen Biotech, Inc. amended Second Amendment to Forward Purchase Agreement with Sandia Investment Management LP valued at Established floor on Reset Price (effective 2024-04-18).

Action
amendment
Agreement
equity purchase
Counterparty
Sandia Investment Management LP
Value
Established floor on Reset Price
Effective
2024-04-18
Exact text from the filing
On April 18, 2024, NKGen Biotech, Inc. (the “Company” and formerly known as Graf Acquisition Corp. IV (“Graf”)) and Seller (defined below) entered into a second amendment (the “Amendment”) to the forward purchase agreement, dated as of September 26, 2023 (the “FPA”) initially among the Company, Graf, and Sandia Investment Management LP (“Sandia”) on behalf of the investors thereto (collectively, “Sellers”) for OTC Equity Prepaid Forward Transactions, as amended on January 19, 2024. Pursuant to the Amendment, the Company and Sellers agreed to establish a floor on the Reset Price (as defined in the Amendment).
View on SEC.gov

268 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR
accession 0001213900-24-035893
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.